Please note: This product is for research use only.
Although the number of Biobanks across the world is increasing rapidly, quality control (QC) of the entire process is crucial to guarantee the value of the biobanks.
Standardization is required to enable scientists to incorporate the results acquired from specimen tests from one or more numbers of biobanks. It also involves a QC process that should cover all facets of pre-analytics and sample storage. Donor/specimen metaparameters should also be validated since it carries additional value.
In particular, NMR can be used to carry out QC-analysis of liquid biopsies. This technique is capable of delivering a huge number of criteria based on a single QC measurement for each sample.
Apart from QC data, the NMR technique can also provide a huge amount of metabolic data using the same spectra produced at the time of the QC process. When this data is used on a urine sample, 150 metabolites in two age ranges can be quantified.
In serum/plasma, 26 metabolites/parameters and 115 lipoprotein-associated parameters (such as subclasses) are investigated and measured. The entire process is automated through push buttons, and can be managed by a trained medical technical assistant.
Example BioBank QC Summary
The following is an extract of the summary page of the B.I.BioBankQC-PS and B.I.BioBankQC-UR report.
Image Credit: Bruker BioSpin - NMR, EPR and Imaging.
IVDR Platform and Its Embedded Solutions
Image Credit: Bruker BioSpin - NMR, EPR and Imaging.
Rich Spectral Information
On the basis of the excellent performance of NMR in terms of transferability and reproducibility, high-quality analysis of data is now available to offer further information for the biobank specimens.
Along with the biobank, tool packages are also provided for the quantification of urine and plasma/serum as stated before. A range of disease-relevant information, lipoprotein information, and endogenous metabolites is delivered. All these were obtained from the QC spectra analysis.
Standardized Reporting
Example of the QC report available from B.I.BioBankTool. Image Credit: Bruker BioSpin - NMR, EPR and Imaging.
Spectra Instead of Aliquots
Based on the concept of IVDr Platform and its stringent standardization for the generation of NMR data, spectra can be selected from various biobanks to widen the testing range of clinical trials, or for many epidemiological studies on a global basis. This offers, for instance, spectra from healthy cohorts out of the biobanks rather than always creating new aliquots.
This approach builds a novel value proposition for biobanks, thus saving costs and contributing to big data efficiently.
Thus, the latest NMR-based diagnostic tests can be verified on numerous phenotypes and on a global basis without increasing the trial cost. This special feature of the NMR has been clearly demonstrated by the data produced from an 11 IVDr platform ringtest.